International Review of Ophthalmology ›› 2023, Vol. 47 ›› Issue (6): 542-547.doi: 10.3760/cma.j.issn.1673-5803.2023.06.012

Previous Articles     Next Articles

Research progress of PANoptosis in the mechanism and treatment of glaucoma

Ye Dan1.2, Xu Yue1, Huang Jingjing1    

  1. 1State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou 510060, China; 2Department of Ophthalmology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
  • Received:2023-06-10 Online:2023-12-22 Published:2023-12-22
  • Contact: Huang Jingjing, Email: hjjing@mail.sysu.edu.cn
  • Supported by:
     National Natural Science Foundation of China (82271081)

Abstract: Glaucoma is a group of irreversible blinding ophthalmopathies characterized by progressive loss of retinal ganglion cells (RGC) and axonal damage. The specific damage mechanism has not been clarified. PANoptosis is an inflammatory cell death pathway, including apoptosis, necroptosis and pyroptosis. There are three activation pathways of cell death and molecular crosstalk in the retina of glaucoma patients and experimental animal models of glaucoma, which are closely related to the occurrence and development of glaucomatous RGC death. Targeted intervention with PANoptotic related molecules can inhibit retinal damage and RGC loss in glaucoma. (Int Rev Ophthalmol, 2023, 47:  542-547)

Key words: glaucoma, PANoptosis, retinal ganglion cells